Top Medical Searches

Lipocine Announces FDA Acknowledgement of Tlando (LPCN 1021) NDA Resubmission

SALT LAKE CITY, Aug. 14, 2017 (GLOBE NEWSWIRE) — Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration (“FDA”) has acknowledged receipt of the Company’s New Drug Application… Read More..

Be Sociable, Share!
August 13th, 2017 Posted in NewDrugs
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us